CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib.

ALL Acute lymphoblastic leukemia CSF3R Dasatinib Ph-like ALL

Journal

Leukemia research reports

ISSN: 2213-0489

Titre abrégé: Leuk Res Rep

Pays: England

ID NLM: 101608906

Informations de publication

Date de publication:
2020

Historique:

received: 13 01 2020

revised: 23 05 2020

accepted: 05 06 2020

entrez: 25 6 2020

pubmed: 25 6 2020

medline: 25 6 2020

Statut: epublish

Résumé

Activating mutations in the gene encoding for receptor of colony stimulating factor 3 (CSF3R) are drivers of pathogenesis in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We describe a patient with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and three unique CSF3R truncating mutations which are predicted to be activating. After a slow early response to induction chemotherapy, dasatinib was added based on data from

Identifiants

DOI: 10.1016/j.lrr.2020.100208 PMID: 32577374 PMC: PMC7305335

pubmed: 32577374

doi: 10.1016/j.lrr.2020.100208

pii: S2213-0489(20)30014-5

pii: 100208

pmc: PMC7305335

doi:

Types de publication

Journal Article

Langues

eng

Pagination

100208

Informations de copyright

Déclaration de conflit d'intérêts

None.

Références

N Engl J Med. 2013 May 9;368(19):1781-90

pubmed: 23656643

Blood Adv. 2020 Jan 14;4(1):218-228

pubmed: 31935290

J Biol Chem. 2018 May 11;293(19):7387-7396

pubmed: 29572350

J Clin Oncol. 2017 Feb;35(4):394-401

pubmed: 27870571

Blood. 2019 Apr 4;133(14):1548-1559

pubmed: 30658992

Blood. 2017 Jan 12;129(2):177-187

pubmed: 27777238

N Engl J Med. 2014 Sep 11;371(11):1005-15

pubmed: 25207766